Oilatum Plus Bath Additive.Light liquid paraffin 52.5% w/wBenzalkonium chloride 6.0% w/wTriclosan 2.0% w/w

Nazione: Irlanda

Lingua: inglese

Fonte: HPRA (Health Products Regulatory Authority)

Principio attivo:

Benzalkonium chloride; Triclosan; Light liquid paraffin

Commercializzato da:

GlaxoSmithKline Consumer Healthcare (Ireland) Limited

Codice ATC:

D08AJ; D08AJ01

INN (Nome Internazionale):

Benzalkonium chloride; Triclosan; Light liquid paraffin

Dosaggio:

52.5/6/2 percent weight/weight

Forma farmaceutica:

Bath additive

Tipo di ricetta:

Product not subject to medical prescription

Area terapeutica:

Quaternary ammonium compounds; benzalkonium

Stato dell'autorizzazione:

Marketed

Data dell'autorizzazione:

1989-05-25

Scheda tecnica

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Oilatum Plus Bath Additive.
Light liquid paraffin 52.5% w/w
Benzalkonium chloride 6.0% w/w
Triclosan 2.0% w/w
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Bath additive.
A clear, pale yellow oily solution.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the treatment of infected eczemas and eczemas at risk from
infection.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Oilatum Plus should always be diluted with water. It is an effective
cleanser and should not be used with soap.
Bath: In an eight inch bath add 2 capfuls; in a four inch bath add 1
capful.
Infant bath: Add 1 ml (just sufficient to cover the bottom of the cap)
and mix well with water.
Soak for 15 minutes, gently pat the skin dry with a clean towel. Use
once daily.
4.3 CONTRAINDICATIONS
Patients with known hypersensitivity to any of the ingredients should
not use the product.
Not recommended for babies younger than 6 months.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Avoid contact of the undiluted product with the eyes.
Take care to avoid slipping in the bath.
Light liquid paraffin
52.5
% w/w
Benzalkonium chloride
6.0
% w/w
Triclosan
2.0
% w/w
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_1_
_/_
_1_
_1_
_/_
_2_
_0_
_1_
_6_
_C_
_R_
_N_
_ _
_2_
_1_
_8_
_4_
_6_
_7_
_5_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER F